R. Röckert

发表

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study

H. Sorbye, M. Bärlund, P. Flygare, 2022, ESMO open.

O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors

H. Sorbye, P. Flygare, B. Glimelius, 2020 .

Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).

H. Sorbye, P. Flygare, B. Glimelius, 2024, Acta oncologica.